Enzastaurin (LY317615) + Carboplatin
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent Gliomas
Conditions
Recurrent Gliomas
Trial Timeline
Jan 1, 2007 → Jul 1, 2013
NCT ID
NCT01445119About Enzastaurin (LY317615) + Carboplatin
Enzastaurin (LY317615) + Carboplatin is a phase 1 stage product being developed by Eli Lilly for Recurrent Gliomas. The current trial status is completed. This product is registered under clinical trial identifier NCT01445119. Target conditions include Recurrent Gliomas.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent Gliomas were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01445119 | Phase 1 | Completed |
Competing Products
20 competing products in Recurrent Gliomas